GSK vs. TECH: GSK vs. Bio-Techne Stock Comparison

Company Profile

GSK (GSK) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both GSK (GSK) at 28.27% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both GSK (GSK) at 12.97% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

GSK (GSK) at 32.14% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both GSK (GSK) at 4.11% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both GSK (GSK) at 123.15% and Bio-Techne (TECH) at 152.17% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both GSK (GSK) at 0.86 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Bio-Techne (TECH) at 0.13 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both GSK (GSK) at 1.57% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both GSK (GSK) at 63.33% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both GSK (GSK) at 4.02 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics